Table 2. In vitro cross-neutralization of α7 mucosal hr and lr HPV by antisera raised against 18L1–45RG1 VLP using L2-based pseudovirion neutralization assay.
| 18L1–45RG1 VLP sera | type-specific VLP/PsV serum | HPV18L1 VLP serum | |||
|---|---|---|---|---|---|
| #1 | #2 | ||||
| Pseudovirion | Neutralization Titer | ||||
| HPV16 | hr α9 | 0 | 0 | 10,000 | 0 |
| HPV31 | hr α9 | 0 | 0 | 10,000 | 0 |
| HPV18 | hr α7 | 10,000 | 10,000 | 100,000 | 100,000 |
| HPV39 | hr α7 | 100 | 100 | 1,000,000 | 0 |
| HPV45 | hr α7 | 1,000 | 1,000 | 1,000,000 | 1,000 |
| HPV59 | hr α7 | (25) | 0 | 1,000,000 | 0 |
| HPV68 | hr α7 | 0 | 100 | 1,000,000 | 0 |
| HPV70 | lr α7 | 1,000 | 100 | 1,000,000 | 0 |